|
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases, is holding a press conference today to announce plans for the commencement of the company’s clinical trial program at Innovation Boulevard located in Surrey, British Columbia.
Today’s announcement marks the beginning of an intensive research review into NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion – Israel Institute of Technology which has been in-licensed by Breathtec. The system has been developed to detect the volatile biomarkers of diseases from exhaled breath, and Breathtec has chosen the Province of British Columbia and the City of Surrey to hold its clinical trials for selected respiratory infections at the Health & Technology District on Innovation Boulevard.
“Breathtec’s exciting technology, developed in Israel, is going through the highest quality clinic trials right here in British Columbia,” said Minister of Technology, Innovation and Citizens’ Services, Amrik Virk. “We have a vibrant tech sector attracting companies from clean tech, to information and communications systems, to life sciences – this kind of innovative work is a key part of our diversified economy.”
“The City of Surrey supports the development of health technologies and we welcome Breathtec Biomedical to our growing stable of health technology specialist firms,” said Mayor Linda Hepner. “The addition of Breathtec is another example of how the City of Surrey is committed to working together to help take innovative science and technology ideas off the drawing board and turning them into real working solutions that will improve the quality of life for all.”
Breathtec CEO, Mr. Guy LaTorre states, “We are delighted to come to the City of Surrey, British Columbia and to have the opportunity to access such a world-class facility and team. The Na-Nose device is an exciting new late stage technology that has already been clinically proven in the early detection of cancer and has the potential to change the way we diagnose respiratory diseases which will be our company’s focus.”
During the event, NA-NOSE lead researcher Professor Hossam Haick will demonstrate how the nanotechnology-based breath analysis system is used for screening of potentially life-threatening diseases. The licensed technology will be clinically evaluated as a non-invasive point of care device for early detection of community and hospital based infections such as Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold, etc.
Press Conference – Tuesday, June 28th at 11 a.m. (PDT), 2 pm (EDT).
Where: City Centre 1, 13737 96th Avenue, HealthTech Innovation Hub (2nd Floor), Surrey, Canada.
In Attendance:
- Honourable Minister Amrik Virk, Minister of Technology, Innovation and Citizens’ Services
- Mayor Linda Hepner, City of Surrey
- Guy LaTorre, Chief Executive Officer, Breathtec Biomedical
- Dr. Hossam Haick, Professor in Chemical Engineering and Nanotechnology at Technion -Israel Institute of Technology (product demonstrations)
- Dr. Raj Attariwala, MD, PhD., Lead Engineer, Breathtec Biomedical
Innovation Boulevard is an agile partnership of health, business, higher education and government coming together and creating new health technologies to improve peoples’ lives through a shared vision to achieve innovative results, improve health outcomes for patients, implement intelligent solutions for the health care economy, attract talented clinicians and researchers, and to grow companies in the health care technology and services sector.
Breathtec Biomedical Announces Plans for Breath Analysis Clinical Trials at Canadian Tech Facility – Select Here to Read More
Professor Haick is best known for developing the NA-NOSE technology that can be used to detect disease by mechanically “smelling” elements in the breath of potential sufferers. Certain diseases produce chemicals called volatile organic compounds (VOCs), which easily evaporate into the air and produce a discernible scent profile. Haick’s Na-NOSE chip detects the unique “signature” of VOCs in exhaled breath.
The Na-NOSE technology was created as the “Breath Test Being Developed To Detect Lung Cancer”: Read More about the Na-NOSE technology that BTHCF has licensed for Infectious Disease
In related news, Professor Dr. Haick has recently been acclaimed as one of the world’s most “Good” people, as noted by GOOD Magazine, an international publication that recognizes researchers for the benefits of their work for humanity. According to the magazine publishers, Haick is one of the 100 most influential people in the world who are changing the world in a positive manner. The GOOD 100 are “spearheading change” in the areas of science, education, and business, said the magazine, and Haick, among them, “refuses to accept the existing reality as the end of the story. Not one of the 100 people we have chosen operates out of a desire for fame — which is precisely why it is important to recognize their activity.”
Potential Investors take note, BTHCF is becoming a global company specializing in breath testing technology created and licensed for the early detection of infectious diseases. The potential return for early shareholders is lucrative as this early Bio-Tech company begins clinical trials for the Na-Nose device!
Besides the GOOD recognition, Dr. Haick was also recently presented with the Humboldt Research Award, which recognizes top research done throughout the world in cooperation with research institutes in Germany. Awarded by the Alexander von Humboldt Foundation, the prize is given to prominent researchers who have significantly influenced their fields of study in cooperation with research institutes in Germany. It is granted in recognition of a researcher’s achievements as a whole — discoveries, theories, and insights.
Dr. Hossam Haick joins BTHCF after receiving the Humboldt Research Award in Germany and being named one of the 100 most influential people in the world! Select here to read more
Mr. Kal Malhi, President of Breathtec Biomedical notes, “We are truly excited by the prospects ahead. This agreement represents a major leap forward in our quest to commercialize the best breath analysis technologies for the detection of disease. Our technical partners are world-class, and with the expert direction of Prof. Haick we are extremely well served. With the close of this agreement we are rapidly moving ahead and arrangements to ship the prototype technology to our research and development team are already underway.”
“Breathtec has received international attention regarding our innovative breath testing technologies and recent NA-NOSE technology partnership with the Technion – Israel Institute of Technology. With today’s announcement we have also significantly increased our international visibility in the capital markets,” said Mr. Kal Malhi, President of Breathtec Biomedical. “This is a major step forward as it positions the Company on a proven trading platform with access to a broad segment of the American investment community which builds upon our current exposure to Canadian and European markets. As a result, we are moving ahead and rapidly furthering development of our novel technologies in readiness for what we perceive is a global marketplace opportunity.”
BreathTec Biomedical Inc.
Stock Trading Symbol:
(America: BTHCF) (Canada: BTH) (Frankfurt: BTI)
Learn more about BTHCF and the opportunity for early investors – Select Here
|
